278 related articles for article (PubMed ID: 11520654)
1. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.
Meigs JB; Mohr B; Barry MJ; Collins MM; McKinlay JB
J Clin Epidemiol; 2001 Sep; 54(9):935-44. PubMed ID: 11520654
[TBL] [Abstract][Full Text] [Related]
2. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
3. Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.
Egan KB; Suh M; Rosen RC; Burnett AL; Ni X; Wong DG; McVary KT
Int J Clin Pract; 2015 Nov; 69(11):1316-25. PubMed ID: 26215544
[TBL] [Abstract][Full Text] [Related]
4. Physical activity and benign prostatic hyperplasia.
Platz EA; Kawachi I; Rimm EB; Colditz GA; Stampfer MJ; Willett WC; Giovannucci E
Arch Intern Med; 1998 Nov; 158(21):2349-56. PubMed ID: 9827786
[TBL] [Abstract][Full Text] [Related]
5. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia.
Platz EA; Rimm EB; Kawachi I; Colditz GA; Stampfer MJ; Willett WC; Giovannucci E
Am J Epidemiol; 1999 Jan; 149(2):106-15. PubMed ID: 9921955
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
7. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
Hammarsten J; Högstedt B
Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
[TBL] [Abstract][Full Text] [Related]
8. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
[TBL] [Abstract][Full Text] [Related]
9. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.
Dahle SE; Chokkalingam AP; Gao YT; Deng J; Stanczyk FZ; Hsing AW
J Urol; 2002 Aug; 168(2):599-604. PubMed ID: 12131317
[TBL] [Abstract][Full Text] [Related]
10. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
Hammarsten J; Högstedt B
Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
[TBL] [Abstract][Full Text] [Related]
11. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J
J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304
[TBL] [Abstract][Full Text] [Related]
13. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
15. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract][Full Text] [Related]
16. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia.
Crispo A; Talamini R; Gallus S; Negri E; Gallo A; Bosetti C; La Vecchia C; Dal Maso L; Montella M
Urology; 2004 Oct; 64(4):717-22. PubMed ID: 15491708
[TBL] [Abstract][Full Text] [Related]
17. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
18. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
19. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
Pearson JD; Luderer AA; Metter EJ; Partin AW; Chan DW; Fozard JL; Carter HB
Urology; 1996 Dec; 48(6A Suppl):4-9. PubMed ID: 8973693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
